Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.

Nikolaus Benjamin WagnerBenjamin WeideMirko GriesMaike ReithKathrin TarnanidisValerie SchuermansCharlotte KemperCoretta KehrelAnne FunderRamtin LichtenbergerAntje SuckerEsther HerpelTim Holland-LetzDirk SchadendorfClaus GarbeViktor UmanskyJochen UtikalChristoffer Gebhardt

Published in: Journal for immunotherapy of cancer (2019)

The tumor microenvironment-associated protein S100A8/A9 serves as a novel prognostic marker for metastasis and survival of metastatic melanoma patients and predicts response to immunotherapy with pembrolizumab. These data underscore the significance of tumor microenvironment-derived factors as suitable biomarkers for melanoma.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
machine learning
patient reported outcomes